Bichlien Nguyen

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue

Anna Sapino, Paul Roepman, Sabine C. Linn et al. · Journal of Molecular Diagnostics · 2014 · 116 citations · Full text

Histopathology, Mammaprint Molecular Diagnostics, Pathology +4

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Pat W. Whitworth, Lisette Stork‐Sloots, Femke A. de Snoo et al. · Annals of Surgical Oncology · 2014 · 88 citations · Full text

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

Bichlien Nguyen, P. Cusumano, Kenneth Deck et al. · Annals of Surgical Oncology · 2012 · 45 citations

Breast Oncology, Cancer Detection, Local Clinical Subtyping +9

Bevacizumab and Albumin-Bound Paclitaxel Treatment in Metastatic Breast Cancer

John S. Link, James Waisman, Bichlien Nguyen et al. · Clinical Breast Cancer · 2007 · 32 citations

Metastatic Breast Cancer, Breast Oncology, Medicine +4